SBIR/STTR Research Award
BIODEGRADABLE MICROSPHERES FOR CANCER IMMUNOTHERAPY
Award amount
$99,906Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- T & B BIOCLONE, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION: A novel technology for the local and sustained delivery of
immunostimulatory molecules to the tumor environment for cancer immunotherapy
is evaluated. The ability of biodegradable polymer micro spheres loaded with
murine Interleukin- 12 to promote the regression of established tumors and
distant metastatic lesions is investigated in a syngeneic murine tumor model.
The feasibility of this new sustained delivery system has ahead been
established by demonstrating that different cytokines can be loaded into and
released from the micro spheres in a biologically active form both in vitro and
in vivo. Our objective here is to test our patent-protected cytokine-loaded
micro spheres for their ability to deliver cytokines to established tumors and
thereby eliminate tumors and provoke an antitumor immunity. In Aim 1,
intralesional injections of IL-12- loaded micro spheres are employed to induce
the suppression and/or regression of established primary tumors with the
concomitant development of protective antitumor immunity. In Aim 2, the
protocols that are found to be effective in Aim 1 are tested for their ability
to promote the suppression of established lung metastases in a clinically
relevant spontaneous metastasis model. The results from these Phase I studies
are expected to establish whether cytokine-loaded micro spheres represent a
simpler, more versatile and clinically feasible alternative to gene-modified
tumor cell vaccines for adjuvant cytokine immunotherapy of cancer.
PROPOSED COMMERCIAL APPLICATION:
If proven effective, our tumor vaccination approach involving cytokine-loaded microspheres
will provide a simple and universally applicable alternative to cumbersome and very
expensive cytokine gene therapy strategies that are currently being tested in human
clinical trials. This treatment has the potential to become a widely utilized adjuvant therapy
to current standard treatments for cancer.
Technology keywords
Not reported